Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells $20,516.40 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 695 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total value of $20,516.40. Following the transaction, the general counsel now owns 144,299 shares of the company’s stock, valued at approximately $4,259,706.48. This trade represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Apellis Pharmaceuticals Trading Up 3.3 %

Shares of Apellis Pharmaceuticals stock traded up $0.99 during trading hours on Thursday, hitting $30.46. The company’s stock had a trading volume of 232,907 shares, compared to its average volume of 1,954,741. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90. The firm has a fifty day moving average of $32.20 and a 200-day moving average of $32.96. The stock has a market cap of $3.79 billion, a price-to-earnings ratio of -14.99 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. During the same period in the previous year, the company posted ($1.17) EPS. Apellis Pharmaceuticals’s revenue was up 78.3% on a year-over-year basis. Research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on APLS shares. Mizuho decreased their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, October 24th. William Blair assumed coverage on Apellis Pharmaceuticals in a report on Wednesday, October 16th. They set an “outperform” rating on the stock. Evercore ISI upgraded Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Citigroup decreased their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, January 14th. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently bought and sold shares of APLS. KBC Group NV increased its holdings in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after acquiring an additional 679 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after buying an additional 781 shares during the last quarter. Wolverine Asset Management LLC purchased a new position in Apellis Pharmaceuticals during the 3rd quarter worth approximately $27,000. True Wealth Design LLC purchased a new position in Apellis Pharmaceuticals during the 3rd quarter worth approximately $27,000. Finally, Toronto Dominion Bank grew its stake in Apellis Pharmaceuticals by 4.2% during the 3rd quarter. Toronto Dominion Bank now owns 25,622 shares of the company’s stock worth $739,000 after buying an additional 1,022 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).